Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.
Zachariae, Claus, Kenneth Gordon, Alexandra B Kimball, Mark Lebwohl, Andrew Blauvelt, Craig Leonardi, Daniel Braun, Missy McKean-Matthews, Russel Burge, and Gregory Cameron. 2018. “Efficacy and Safety of Ixekizumab over 4 years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis.”. Journal of the American Academy of Dermatology 79 (2): 294-301.e6.